NASDAQ:TRAW Traws Pharma (TRAW) Stock Price, News & Analysis $0.18 -0.06 (-23.91%) Closing price 11/20/2026 04:00 PM EasternExtended Trading$0.19 +0.01 (+8.00%) As of 11/20/2026 07:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOwnershipSEC Filings About Traws Pharma Stock (NASDAQ:TRAW) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Traws Pharma alerts:Sign Up Key Stats Today's Range$0.17▼$0.2350-Day Range$0.18▼$0.6352-Week Range$0.17▼$3.23Volume381,861 shsAverage Volume197,559 shsMarket Capitalization$2.69 millionP/E RatioN/ADividend YieldN/APrice Target$1.00Consensus RatingReduce Company Overview Traws Pharma is a clinical-stage biopharmaceutical company developing medicines for viral diseases and cancer. Its research includes antiviral candidates aimed at respiratory infections such as COVID-19 and influenza, as well as treatments for cancer. The company’s pipeline includes narazaciclib, an investigational CDK4/6 inhibitor being studied for cancer, and antiviral drug candidates designed to target SARS-CoV-2 and influenza. These products remain in development and are not established as approved treatments. Traws Pharma was formed in 2024 through the combination of Trawsfynydd Therapeutics and Onconova Therapeutics; the combined company adopted the Traws Pharma name. Its predecessor, Onconova, had focused on developing cancer therapies.AI Generated. May Contain Errors. Read More Traws Pharma Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks43rd Percentile Overall ScoreTRAW MarketRank™: 2.144744160175 of 5 starsTraws Pharma scored higher than 43% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.1 / 5Analyst RatingReduce Consensus RatingTraws Pharma has received a consensus rating of Reduce. The company's average rating score is 1.80, and is based on no strong buy ratings, no buy ratings, 4 hold ratings, and 1 sell rating.Upside PotentialTraws Pharma has a consensus price target of $1.00, representing about 471.4% upside from its current price of $0.18.Amount of Analyst CoverageTraws Pharma has only been the subject of 1 research reports in the past 90 days.Read more about Traws Pharma's stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthN/A Earnings GrowthEarnings for Traws Pharma are expected to remain at ($1.01) per share in the coming year. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted4.87% of the float of Traws Pharma has been sold short.Short Interest Ratio / Days to CoverTraws Pharma has a short interest ratio ("days to cover") of 4.14.Change versus previous monthShort interest in Traws Pharma has recently decreased by 0.30%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldTraws Pharma does not currently pay a dividend.Dividend GrowthTraws Pharma does not have a long track record of dividend growth. News and Social Media4.3 / 5News Sentiment0.92 News SentimentTraws Pharma has a news sentiment score of 0.92. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.42 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 11 news articles for Traws Pharma this week, compared to 2 articles on an average week.Search Interest2 people have searched for TRAW on MarketBeat in the last 30 days. MarketBeat Follows7 people have added Traws Pharma to their MarketBeat watchlist in the last 30 days. Company Ownership0.4 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Traws Pharma insiders have not sold or bought any company stock.Percentage Held by Insiders8.73% of the stock of Traws Pharma is held by insiders.Percentage Held by Institutions7.95% of the stock of Traws Pharma is held by institutions.Read more about Traws Pharma's insider trading history. Receive TRAW Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Traws Pharma and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. TRAW Stock News HeadlinesBrokers Set Expectations for Traws Pharma FY2026 Earnings2 hours ago | americanbankingnews.comTraws Pharma, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2026November 17, 2026 | marketscreener.comMI'm handing you this stock todayElon doesn't own the chip inside his Teslas or Starlink dishes. He licenses it from one little known public company. Now he's planning 1,000,000 AI satellites in orbit, and every one could pay this company a royalty. Analyst Dylan says the window to get in closes around December 8th, before new money floods into the buildout. | Behind the Markets (Ad)Traws Pharma, Inc. (NASDAQ:TRAW) Stock Has Average Price Target of $1.00 According to BrokeragesNovember 17, 2026 | americanbankingnews.comTraws Pharma Reports Positive Phase 2a Ratutrelvir Results and Advances Tivoxavir Marboxil DevelopmentNovember 16, 2026 | quiverquant.comQTraws Pharma Reports Third Quarter 2026 Financial Results and Provides Business HighlightsNovember 16, 2026 | globenewswire.comTraws Pharma Reports Final Phase 2a Results for Ratutrelvir in COVID-infected Subjects, Showing Fewer Treatment-Related Adverse Events and No Viral Rebounds Versus PAXLOVID®November 12, 2026 | globenewswire.comTraws Pharma (TRAW) vs. Its Competitors Financial AnalysisNovember 11, 2026 | americanbankingnews.comSee More Headlines TRAW Stock Analysis - Frequently Asked Questions How have TRAW shares performed this year? Traws Pharma's stock was trading at $1.13 on January 1st, 2026. Since then, TRAW shares have decreased by 84.5% and is now trading at $0.1750. How were Traws Pharma's earnings last quarter? Traws Pharma, Inc. (NASDAQ:TRAW) issued its quarterly earnings results on Monday, November, 16th. The company reported ($0.18) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.21) by $0.03. When did Traws Pharma IPO? Traws Pharma (TRAW) raised $67 million in an initial public offering (IPO) on Thursday, July 25th 2013. The company issued 5,166,667 shares at $12.00-$14.00 per share. How do I buy shares of Traws Pharma? Shares of TRAW stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Company Calendar Last Earnings11/16/2026Today11/20/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Red Zone (4m+) 1-Year History Nov 25 Feb 26 May 26 Aug 26 Nov 26 TRAW's financial health is in the Red zone, according to TradeSmith. TRAW has been in this zone for over 4 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Pharmaceuticals Sub-IndustryPharmaceuticals Current SymbolNASDAQ:TRAW Previous SymbolNASDAQ:TRAW CIK1130598 Webwww.trawspharma.com Phone267-759-3680Fax267-759-3681Employees7Year FoundedN/APrice Target and Rating Average Price Target for Traws Pharma$1.00 High Price Target$1.00 Low Price Target$1.00 Potential Upside/Downside+471.4%Consensus RatingReduce Rating Score (0-4)1.80 Research Coverage5 Analysts Profitability EPS (Trailing Twelve Months)($1.58) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$9.17 million Net MarginsN/A Pretax Margin-710.83% Return on Equity-23,868.92% Return on Assets-171.09% Debt Debt-to-Equity RatioN/A Current Ratio0.93 Quick Ratio0.93 Sales & Book Value Annual Sales$2.79 million Price / Sales0.96 Cash Flow$0.51 per share Price / Cash Flow0.34 Book Value($0.07) per share Price / Book-2.50Miscellaneous Outstanding Shares15,370,000Free Float14,026,000Market Cap$2.69 million OptionableNo Data Beta1.67 The 7 Hottest IPO Stories of 2026MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.Get This Free Report This page (NASDAQ:TRAW) was last updated on 11/20/2026 by MarketBeat.com Staff. From Our PartnersYour $7 scanner is waitingThe Instant Scanner is $7 in Bill Poulos's Black Friday sale. Every night it delivers a list showing which sto...Profits Run | SponsoredTop Trader Reveals Stunning Black Friday DealOthers paid $500 for the Snapback Indicator. This Black Friday, it's available for just $7. Base Camp Tradi...Base Camp Trading | SponsoredToday's free pick (on me)Elon Musk doesn't own the chip inside every Tesla, Starlink dish, and AI satellite - he licenses it from one l...Behind the Markets | SponsoredBeyond NVDA: The World’s Next #1 Company?This small-cap trades in an overlooked corner of the market, with a market cap more than 600X smaller than Nvi...Banyan Hill Publishing | SponsoredELON + YOU + DECEMBER 8THElon Musk's next big project may be the most ambitious move of his career, and all signs point to December 8th...Paradigm Press | SponsoredCFA: Bank of America Said THISOn January 24th, 2022, Bank of America told Bloomberg something that should terrify every American with a savi...Decentralized Masters | SponsoredThe investigation Porter spent tens of thousands to documentPorter Stansberry flew the Porter and Co. team 3,300 miles to Dublin to investigate a 17-year investing experi...Porter & Company | SponsoredThe next convergence is hereIn 2006, a flooded mine at Cigar Lake sent uranium prices from the $50 range to $136 in eight months. This pa...Digest Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Traws Pharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Traws Pharma With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.